Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive

Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.

29/435 Coincidencias para
“Bariatric surgery”

“Bariatric surgery” Borrar todo
  1. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Coinc. 100

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  2. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. Key publication

    Codjia T et al. · Obes Surg · 2021 Coinc. 99

    ### Background Bariatric surgery is among the therapeutic options for non-alcoholic fatty…

    FibroTest NashTest SteatoTest Metabolic

  3. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.

    Lassailly G et al. · Eur J Gastroenterol Hepatol · 2011 Coinc. 97

    …cohort of patients treated with bariatric surgery, were included. Histology (NAFLD activity…

    FibroTest NashTest SteatoTest Metabolic

  4. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

    Bedossa P et al. · Hepatology · 2012 Coinc. 95

    …biopsy at the time of bariatric surgery was studied. An algorithm for…

    Metabolic

  5. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication

    Poynard T et al. · Diagnostics (Basel) · 2025 Coinc. 94

    **Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…

    FibroTest-T2D Metabolic

  6. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Coinc. 92

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  7. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Coinc. 90

    ActiTest AshTest FibroTest NashTest +6

  8. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Coinc. 88

    FibroTest SteatoTest Metabolic

  9. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Coinc. 87

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…

    NashTest SteatoTest Metabolic

  10. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis

    Poynard T et al. · PLoS One · 2012 Coinc. 85

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    ActiTest FibroTest NashTest SteatoTest +1

  11. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Coinc. 83

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  12. An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

    Poynard T et al. · Biomedicines · 2025 Coinc. 82

    **Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  13. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Coinc. 80

    ### Unlabelled Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance…

    SteatoTest Metabolic

  14. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Coinc. 78

    ### Background Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor…

    FibroTest NashTest SteatoTest Metabolic

  15. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Coinc. 76

    ### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  16. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Coinc. 75

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  17. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication

    Deckmyn O et al. · Biomedicines · 2022 Coinc. 73

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  18. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Coinc. 71

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  19. Peta V, Ziol M, Imbert-Bismut F, et al., for the FibroFrance-GHPS-HECAM group

    Valentina Peta et al. · GastroHep · 2019 Coinc. 69

    FibroTest LCR1 LCR2 Alcohol +3

  20. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Coinc. 68

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  21. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Coinc. 66

    ### Background African Americans have lower reported likelihood of hepatitis C virus-related…

    ActiTest FibroTest HCV

  22. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Coinc. 64

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  23. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Coinc. 63

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  24. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Coinc. 61

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  25. The non-invasive assessment of hepatic fibrosis. Review

    Gheorghe G et al. · J Formos Med Assoc · 2021 Coinc. 59

    Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…

    ActiTest FibroTest Alcohol HBV +2

  26. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Coinc. 57

    ### Objective There is a controversy about the performance of blood tests for…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  27. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Coinc. 56

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  28. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review

    Vilar-Gomez E et al. · J Hepatol · 2018 Coinc. 54

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  29. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Coinc. 52

    FibroTest Alcohol HBV HCV +3

Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.